Holen Sie sich die Stockscreener-App
2.46
1.86%
-0.04
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com UK
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Canada
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative
Sixteen lupus patients had no severe immune reactions in early cell-therapy data - Stock Titan
Fate Therapeutics Market Sentiment - Benzinga España
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Fate Therapeutics stock holds steady as investors watch cash runway and pipeline - AD HOC NEWS
FATE Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusPost-Earnings Drift - vinanet.vn
A lupus trial that could support approval is on Fate Therapeutics’ agenda Sept. 9. - Stock Titan
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics stock stabilizes after autoimmune CAR-T safety shock - ad-hoc-news.de
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE) - Seeking Alpha
574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
symbol__ Stock Quote Price and Forecast - CNN
Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et
Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn
Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International
Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com
Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView
Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative
Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan
FATE THERAPEUTICSPATIENTS TO RECEIVE SINGLE 900 MLN-CELL DOSE OF FT819; PRIMARY ENDPOINT AT WEEK 26 - webull.com
FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget
Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo! Finance Canada
Fate Therapeutics Reports Q2 2026 10-Q Filing Highlighting iPSC Pipeline and Key Risks - Kalkine Media
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Fate Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises - TradingView
Fate Therapeutics Reports $30.2 Million Second-Quarter Net Loss - Quiver Quantitative
Fate Therapeutics reports Q2 2026: $2.1M revenue, $30.2M net loss, cash $153.8M - TradingView
Fate Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - tradingview.com
Fate Therapeutics (FATE) Short Interest & Short Float | Updated Aug 2026 $FATE - MarketBeat
FATE Stock Price and Chart — NASDAQ:FATE - TradingView
Renaissance Technologies LLC Increases Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Don't Ignore The Insider Selling In Fate Therapeutics - webull.com
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):